Achaogen Inc (NASDAQ:AKAO) hit a new 52-week low on Friday . The stock traded as low as $6.16 and last traded at $6.21, with a volume of 639921 shares. The stock had previously closed at $6.34.
Several equities research analysts recently weighed in on the company. ValuEngine downgraded Achaogen from a “hold” rating to a “sell” rating in a report on Tuesday, July 10th. Zacks Investment Research upgraded Achaogen from a “strong sell” rating to a “hold” rating in a research report on Thursday. Mizuho reiterated a “buy” rating on shares of Achaogen in a research report on Thursday, May 3rd. Needham & Company LLC cut Achaogen from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. Finally, Guggenheim cut Achaogen from a “buy” rating to a “neutral” rating and set a $17.00 price objective for the company. in a research report on Monday, May 7th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $19.62.
The stock has a market capitalization of $286.63 million, a PE ratio of -1.96 and a beta of 0.83. The company has a quick ratio of 7.01, a current ratio of 3.79 and a debt-to-equity ratio of 0.42.
A number of large investors have recently added to or reduced their stakes in AKAO. Stifel Financial Corp purchased a new position in Achaogen in the first quarter worth $134,000. MetLife Investment Advisors LLC purchased a new position in shares of Achaogen in the fourth quarter valued at $151,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Achaogen in the first quarter valued at $207,000. Granite Investment Partners LLC purchased a new position in shares of Achaogen in the first quarter valued at $211,000. Finally, Two Sigma Investments LP purchased a new position in shares of Achaogen in the fourth quarter valued at $260,000. Hedge funds and other institutional investors own 68.74% of the company’s stock.
Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Featured Story: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.